| Literature DB >> 19232130 |
Shi-qian Zhang1, Hao Yu, Lin-lin Zhang.
Abstract
BACKGROUND: Cervical cancer is the most common malignant gynecological cancer, and lymphatic metastasis can occur in the early stage of tumor growth. Lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), a marker for lymphatic endothelium, provides powerful tools for studying tumor lymphangiogenesis. The purpose of this study is to investigate the clinical implications of lymphangiogenesis in the metastasis of early-stage invasive cervical carcinoma.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19232130 PMCID: PMC2650709 DOI: 10.1186/1471-2407-9-64
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Figure 1Morphology of lymphatic vessels in cervical cancer tissue. (A) The lymph vessels of the normal cervix control were open and regular (arrow). Primary antibody: LYVE-1 polyclonal antibody, magnification: ×200. (B) Blood vessel endothelial cells, negative by immunostaining, with some red blood cells in the capillary lumen (arrow). Primary antibody: LYVE-1 polyclonal antibody, magnification: ×400. (C) The intratumoral lymph vessels were small and collapsed (←); in contrast, the peritumoral lymphatics were often dilated, and irregularly shaped (→). Primary antibody: LYVE-1 polyclonal antibody, magnification: ×200. (D) Some invading cancer cells were present in lymph vessels (star). Primary antibody: LYVE-1 polyclonal antibody, magnification: ×400.
Association of LVD and other clinical and pathological parameters. P, t-test; P*, one-way ANOVA test; P**, Kruskal-Wallis test.
| ILVD | PLVD | ||||
|---|---|---|---|---|---|
| Variables | mean ± SD | mean ± SD | |||
| Catamenia | |||||
| Premenopause | 29 | 7.83 ± 1.10 | 0.292 | 9.17 ± 0.80 | 0.358 |
| Postmenopause | 12 | 7.42 ± 1.12 | 8.92 ± 0.79 | ||
| Tumor size (cm) | |||||
| ≤ 4 | 26 | 7.58 ± 1.06 | 0.528 | 9.08 ± 0.84 | 0.831 |
| > 4 | 15 | 7.93 ± 1.22 | 9.13 ± 0.74 | ||
| Stromal invasion | |||||
| ≤ 2/3 | 17 | 7.35 ± 0.86 | 0.089 | 8.94 ± 0.75 | 0.298 |
| > 2/3 | 24 | 7.96 ± 1.23 | 9.21 ± 0.83 | ||
| FIGO stage | |||||
| Ia | 7 | 6.86 ± 1.07 | 0.075* | 8.57 ± 0.79 | 0.113* |
| Ib | 14 | 8.00 ± 1.24 | 9.07 ± 0.62 | ||
| IIa | 20 | 7.80 ± 0.21 | 9.30 ± 0.86 | ||
| Histological grade | |||||
| HG1 | 7 | 6.57 ± 0.96 | 0.009* | 8.29 ± 0.76 | 0.012** |
| HG2 | 13 | 7.85 ± 1.14 | 9.31 ± 0.63 | ||
| HG3 | 21 | 8.00 ± 0.95 | 9.24 ± 0.77 | ||
| Lymph node metastasis | |||||
| Negative | 26 | 7.38 ± 1.17 | 0.013 | 8.77 ± 0.65 | 0.0002 |
| Positive | 15 | 8.27 ± 0.80 | 9.67 ± 0.72 | ||
| LVI | |||||
| Negative | 35 | 7.54 ± 1.09 | 0.021 | 8.94 ± 0.73 | 0.001 |
| Positive | 6 | 8.67 ± 0.82 | 10.00 ± 0.63 | ||
| Histological cell type | |||||
| SCC | 37 | 7.62 ± 1.14 | 0.139 | 9.14 ± 0.79 | 0.367 |
| ADE | 4 | 8.50 ± 0.58 | 8.75 ± 0.96 | ||
Abbreviation: HG, histological grade; LVI, lymphatic vessel invasion; SCC, squamous cell carcinoma; ADE, adenocarcinoma.